bluuebunny/crossref_metadata_2025_split huggingface dataset:
(288) DOES HAVING ERECTILE DYSFUNCTION IMPACT THE PREFERENCE BETWEEN PENILE CONSTRICTION DEVICES?
Authors: Orozco Rendon D , Saffati G , Whitehead C , Zuckerman C , Hom A , Daily R , Khera M , Cheng P 
Published: December 2024

Abstract

Introduction
Penile constriction devices offer a noninvasive approach to improve sexual performance and erectile function, making them an attractive option for men. With the increasing variety of these devices available on the market, it is crucial to assess and compare patient preferences and device effectiveness to provide valuable insights into their clinical utility and patient satisfaction.

Objective
Our aim was to assess and compare the preference and effectiveness of two medical-grade penile constriction devices between those with erectile dysfunction and those without.

Methods
Between May and July of 2023, males were recruited via social media and prospectively enrolled into an IRB-approved, randomized, questionnaire-based study. Upon enrollment, the participants completed the Sexual Health Inventory for Men (SHIM) and Androgen Deficiency in Aging Males (ADAM). Participants were randomized to which device (FirmTech (FT) vs Eddie by Giddy) they received first. In a two-week timeframe, they used the device twice either during masturbation or intercourse. Once utilized, the participants completed a 17-question, five-point Likert scale device satisfaction questionnaire, in which lower numbers indicated more positive responses. The process was repeated with the second device. Paired T-test and McNemar Chi-Square analysis were run for statistical analysis. A p-value is considered significant if less than 0.05.

Results
Fifty men were enrolled and 49 completed the study. Having some degree of erectile dysfunction (ED) was determined based on SHIM scores &lt;22. After matching the patients 2 to1 by age, 48 were included in the analysis. No significant preferences were determined between having ED and not having ED for the FT device. However, for Eddie by Giddy those with ED felt that they had a higher degree of firmness than those without ED when using the device (Mean Difference (MD): -0.28, p = 0.0244). Both those with ED and without ED would be more likely to use FT in partnered sexual activity than Eddie by Giddy (MD: -0.53, p = 0.0171 and MD: -0.94, p = 0.0178). Table 1 summarizes other selected responses from the questionnaire.

Conclusions
The findings suggest that Eddie by Giddy may have an advantage in improving firmness for those with ED. However, when it comes to using the devices in partnered sexual activity regardless of ED status, both cohorts were more likely to use FT.

Disclosure
Yes, this is sponsored by industry/sponsor: FirmTech.
Clarification: Industry funding only - investigator initiated and executed study.
Any of the authors act as a consultant, employee or shareholder of an industry for: FirmTech.
(291) NOVEL PENILE TUMESCENCE MONITORING DEVICE OBJECTIVELY DEMONSTRATES SHORTER-LASTING SPONTANEOUS ERECTIONS IN MEN WITH ERECTILE DYSFUNCTION
Authors: Jimbo M , Liang S , Daily R , Schardein J , Manektala Y , Gross K 
Published: December 2024

Abstract

Introduction
Tools to assess a man’s erectile function (EF) are currently limited. The Sexual Health Inventory of Men (SHIM) is a validated questionnaire that is easy to administer, but suffers from significant subjectivity, need for patient to actively attempt intercourse, and inability to distinguish vasculogenic from psychogenic erectile dysfunction (ED). Penile Doppler ultrasound (US) can provide objective measurements of cavernosal arterial blood flow, but suffers from high cost, invasiveness, and unreliability in the setting of suboptimal erections. The presence of nocturnal, spontaneous erections is considered a marker of EF, but is difficult to objectively measure. The FirmTech Tech Ring is a novel penile constriction ring with built-in sensors that connect with a smartphone app to record the number and duration of erections.

Objective
We conducted a small pilot study to assess the utility of the FirmTech Tech Ring to measure the quality of spontaneous, overnight erections in men.

Methods
Following Institutional Review Board approval, 9 male patients (aged 23–82 years) presenting to a Men’s Health clinic were recruited. 7 patients endorsed ED and 2 patients denied ED. Each patient was asked to fill out a SHIM, then provided with a device and asked to wear it overnight while asleep. Data were collected through the smartphone app and sent to a centralized database. Pearson’s correlation coefficient was used to determine the association between SHIM scores and erection parameters. 1-way ANOVA was used to compare the +ED and -ED groups.

Results
There were no significant correlations between SHIM scores and the measured parameters (# of overnight spontaneous erections; average duration of each erection). However, when comparing the +ED group against the -ED group, the former had significantly shorter average duration of erections (23.8 min vs. 38.9 min, p = 0.018). The number of spontaneous erections/night did not differ between the +ED and -ED groups (2.67 vs. 3, p = 0.77).

Conclusions
We report preliminary data suggesting that the FirmTech Tech Ring may be a convenient, noninvasive tool to objectively measure patients’ EF. Despite the small sample size, we noted that patients with self-reported ED had significantly shorter duration of spontaneous erections compared to patients who denied ED. Additionally, the # and duration of erections have no correlation with SHIM scores, highlighting the latter’s limitation in assessing a patient’s EF. However, further studies with larger patient cohorts, with various severities of ED and comparison against penile Doppler US results, are needed to validate these findings.

Disclosure
Yes, this is sponsored by industry/sponsor: FirmTech Inc.
Clarification: Industry funding only - investigator initiated and executed study.
Any of the authors act as a consultant, employee or shareholder of an industry for: FirmTech Inc.
(301) TREATMENT MODALITIES IN POST-ORGASMIC ILLNESS SYNDROME: A SYSTEMATIC REVIEW
Authors: Chapalamadugu M , Ponce S , Levine S , Stokes C , Radillo K , Paulsen O , Bronson I , Rubin R 
Published: December 2024

Abstract

Introduction
Post Orgasmic Illness Syndrome (POIS) is a rare, poorly understood condition that is characterized by feeling ill after orgasm. Despite its significant impact on quality of life, POIS remains poorly understood, and effective treatment options are limited without clear guidelines. In fact, only 18% of sexual medicine experts report symptom improvement in more than 30% of the patients. Current treatments that have been used to address the various presentations such as flu-like state, mood disturbances and/or irritability, as well as congestion and inflammation. Given the lack of standardized therapeutic approaches, there is a critical need for a systematic review to document and evaluate various treatments tried for POIS management.

Objective
This systematic review aims to evaluate current treatment modalities for POIS and compile solutions that have been studied and tested.

Methods
A search was conducted in June 2024 of three of the most relevant databases (PubMed, Embase, and Scopus) of clinical studies, RCTs and case reports analyzing treatment modalities of patients with diagnosed or suspected POIS.

Results
Of 48 studies found, 14 matched our inclusion criteria. Our systematic review consists of 1 cross-sectional study, 1 cohort study, and 12 case reports. Only one paper included female patients, the rest studied only male patients. Eleven papers discussed pharmacologic treatment modalities, including antihistamines, ibuprofen, NSAIDs, hormone replacement therapy, steroids, SSRIs, alpha-blockers, beta-blockers, calcium channel-blockers, and triptans. Two papers mentioned immune treatment, one being the intracutaneous injection of autologous semen, and the other being intralymphatic immunotherapy with the injection of allergen-specific immunotherapy. One paper mentioned surgical treatment with bilateral epididymectomy and bilateral vasoligation.

Conclusions
The largest limitation to continued research is related to the rarity and low recognizability of POIS; however, POIS research is on the rise. Scientists across the world are collaborating to better understand the pathophysiology behind this condition and investigate treatment modalities to address the associated symptoms. From reassessing the diagnostic criteria to collecting further data on varied presentations and possible treatment options, researchers are hopeful about the future of POIS.

Disclosure
No.
(302) THE PREVALENCE OF PHOSPHODIESTERASE-5 INHIBITOR USAGE IN MEN WITH RETROGRADE EJACULATION
Authors: Zhou C , Mumtaz M , Kulla A , Wiseman B , Campbell K 
Published: December 2024

Abstract

Introduction
Retrograde ejaculation (RE) represents a disruption and reversal in the normal antegrade seminal pathway, frequently resulting in sexual dissatisfaction and potential subfertility among men. Established etiologies of RE include alpha-adrenergic blockers used for benign prostatic hyperplasia (BPH) and certain psychotropic medications; however, the exact mechanism of action is not yet understood. Phosphodiesterase-5 inhibitors (PDE5Is), which like alpha-adrenergic blockers similarly result in vasodilation, are commonly administered for lower urinary tract symptoms, including erectile dysfunction and BPH. Despite their widespread use, there is limited literature exploring the association between PDE5I administration and the onset of retrograde ejaculation.

Objective
The purpose of this study is to elucidate if a relationship exists between PDE5I usage and retrograde ejaculation.

Methods
An IRB-approved retrospective review at a tertiary referral center identified men with a diagnosis of retrograde ejaculation via ICD-9 or ICD-10 codes and through retrograde semen analysis. Exclusion criteria included men without retrograde ejaculation based on semen analysis or electronic health record review. Baseline demographics included comorbidities, medications, and PDE5I usage. Data were analyzed using descriptive statistics and chi-square tests.

Results
Search criteria resulted in 98 male patients with a diagnosis of retrograde ejaculation (93 via ICD-9 or 10 code, 5 confirmed via semen analysis with post-ejaculatory urinalysis) with a mean age of 51.68 ± 15.99 years. 19 of these patients (19.4%) had recorded use of PDE5I at the time of RE diagnosis. 26 of the resulting patients (26.5%) were previously exposed to PDE5Is at the time of RE diagnosis. Men who were previously prescribed PDE5Is were more likely on average to be older at time of diagnosis (58.19 ± 13.31 years, p = 0.016). There were no statistically significant differences in BMI, race, ethnicity, smoking status, or presence of diabetes between men with previous PDE5I usage versus those without (p &gt; 0.062). Of the men exposed to PDE5Is at any point, 34.6% were on sildenafil, 30.8% were on tadalafil, and 34.6% were on a combination of the two. There was no significant difference between concomitant alpha blocker use or use of psychotropic medications in men who had a history of PDE5Is usage compared to those who had not (p &gt; 0.086).

Conclusions
In our findings, 19.4% patients had noted concurrent PDE5I use at the time of diagnosis of retrograde ejaculation. The use of PDE5I therapy is not uncommon in men with retrograde ejaculation. Further prospective studies to navigate this association are warranted.

Disclosure
No.
(304) THE OVER/UNDER OF PEYRONIE’S DISEASE
Authors: Hampton S , Schommer J , Haehn D , Broderick G 
Published: December 2024

Abstract

Introduction
Over/Under is a sportsbook wager term. Peyronie’s disease (PD) affects men of all ages with an estimated prevalence of up to 9% of the population. The Peyronie’s Disease Questionnaire (PDQ) Scale provides an opportunity to assess patient perception of their disease and the impact it has on quality of life. A potential discrepancy between patient-perceived and physician-measured curvature is important aspect of triaging care for patients with PD. Counseling, management and treatment risks are impacted by PD triage.

Objective
To investigate patient accuracy in perceived degree of curvature in Peyronie’s disease. Are patients over estimating or underestimating PD curvature?

Methods
A retrospective chart review was performed on 57 patients with diagnosis of Peyronie’s disease at our institution. Patients in the study completed a Peyronie’s Disease Questionnaire (PDQ) Scale with additional prompts including, but not limited to, penile curvature with erection, number of penile curvatures, and degree of each penile curvature. All patients had office based testing with intracavernous injection of Alprostadil and color duplex Doppler assessment (CDDU). The primary outcome was estimation of concordance of curvature estimated by patient and measured by provider. Patient overestimation was defined as perceived curvature more than 15 degrees greater than measured curvature. Underestimation was defined as patient-estimated curvature 15 degrees less than measured curvature.

Results
Of the 57 patients, 51 patients met study criteria with a completed questionnaire, documented physician-measured curvature, and absence of an hourglass deformity on examination. Patient concordance with physician-measure curvature within 15 degrees was observed in forty patients (78%). Overestimation of curvature was recorded in eight patients (16%), while three patients (6%) underestimated their curvature.

Conclusions
The PDQ Scale is a useful tool in assessing degree of curvature in patients with PD. We carefully selected men who had normal vascular erection responses to Alprostadil in office and compared provider measurements to patient’s home estimate of curvature. Our study finds that in men with no co-existing erectile dysfunction and no hourglass deformities the majority (78%) accurately estimate their penile curvature within 15 degrees of measured curvature. PDQ cannot replace physical examination of Peyronie’s disease or office based intracavernous induced erections as discordance between percieved and measured curvature is 22%.

Disclosure
No.
(307) EXPERT OPINIONS ON INTRACAVERNOSAL INJECTIONS AND THEIR LINK TO PEYRONIE’S DISEASE AND PENILE FIBROSIS: A SURVEY OF SUPS, GURS, AND SMSNA MEMBERS
Authors: Nosé BD , Sury K , Foreman JR , Gross M , Lentz AC 
Published: December 2024

Abstract

Introduction
The development of penile curvature is recognized as a potential adverse effect of intracavernosal injection (ICI) therapy. Literature often cites Peyronie’s disease as a possible consequence of ICI therapy. However, despite this widespread belief, there is a notable lack of data supporting a causal relationship between intracavernosal injection therapy and the onset of Peyronie’s disease.

Objective
To assess the current opinions of experts in sexual medicine, reconstructive urology, and prosthetic urology regarding the association between intracavernosal injection therapy and the development of Peyronie’s disease and penile fibrosis.

Methods
A 20-question survey was digitally distributed to the listservs of members of the Society of Urologic Prosthetic Surgeons (SUPS), Society of Genitourinary Reconstructive Surgeons (GURS) and the Sexual Medicine Society of North America (SMSNA). Responses were collected over an 8-month period allowing for up to three reminder emails to be sent from the participating societies. Results were then analyzed for descriptive statistics.

Results
A total of 100 surveys were completed. 70% of respondents completed fellowships with the most common being GURS. Respondents’ years in practice were evenly distributed with 49% above and 51% below ten years in practice. Overall, 68% of respondents stated that they counsel patients that ICI can cause Peyronie’s disease and 57% stated that they believe ICI causes corporal fibrosis. When looking at respondent demographics, 70% of fellowship trained respondents stated that they counsel patients that ICI can cause Peyronie’s compared to 57% of non-fellowship trained respondents. This was in contrast to priapism for which 40% of respondents stated that they counsel their patients that priapism may result in Peyronie’s disease with no significant difference in respondents’ completion of a fellowship.

Conclusions
The belief that ICI can cause Peyronie’s disease remains prevalent but not unanimous members of SMSMNA, GURS and SUPS. Urologists who have completed a fellowship are more likely to counsel patients on the risk of Peyronie’s and penile fibrosis with the use of ICI.

Disclosure
Any of the authors act as a consultant, employee or shareholder of an industry for: Boston Scientific and Coloplast.
(308) ASSESSING PATIENT SATISFACTION FOLLOWING TUNICAL EXPANSION PROCEDURES FOR PENILE LENGTHENING: AN INITIAL REVIEW
Authors: Feldman-Schultz O , Desouky ES , Katz D , Levine L 
Published: December 2024

Abstract

Introduction
Salvaging penile length procedurally has become a captivating aspect of reconstructive urology and men’s health, addressing both a functional and psychological health. Patients experience penile shortening due to a variety of medical conditions including Peyronie's disease, priapism with corporal fibrosis, or traumatic scarring. Maintaining or restoring penile length has become an option for ensuring satisfactory sexual function and overall quality of life in such patients. Tunical expansion has emerged as a promising surgical technique aimed at elongating the penis via short coordinated incisions within the tunica albuginea. Compilation of postoperative satisfaction following such procedures has been a mystery as no long term follow up on patient fulfillment and performance has been made.

Objective
The purpose of this study is to evaluate the effectiveness of tunical expansion in enhancing penile length when correlated with patient satisfaction, providing a comprehensive analysis of clinical outcomes and potential benefits for patients undergoing TEP.

Methods
7 patients who underwent TEP during IPP placement from 2020-2024 were contacted and provided a phone call survey designed to assess their satisfaction with postoperative penile length. Survey consisted of a 1-5 scale ranging from “highly dissatisfied” to “highly satisfied” on topics including but not limited to postoperative length, curve, sensation, sexual satisfaction, and overall outcome.

Results
4/7 (57%) of men responded to the survey with an overall satisfaction of 4/5, corresponding to a subjective measurement of “satisfied.” In regard to penile length, patients were overall satisfied with an average rating of 75% satisfied. Penile curvature was also measured given the nature of most pathophysiologies. 100% of patients reported “high satisfaction” with their post operative curvature results.

Conclusions
Tunical expansion offers a viable option for improved post operative penile length following contractile pathologies. Our preliminary study shows that in the small group of men who have received the procedure, they are overall satisfied with their post operative penile length results. Further themes also showed high levels of satisfaction among respondents. It should be noted that tunical expansion is a highly technical procedure with known side effects if not done in the properly trained urologist. However, with efficient education and training, TEP can lead to improved post operative penile length satisfaction.

Disclosure
No.
(314) A WRAP UP ON THE HISTORY OF MALE CONDOMS
Authors: Lavold AL , Furtado T , Loeb C , Bash J , Andino J , Jayadevan R , Mills J 
Published: December 2024

Abstract

Introduction
While there are numerous options for female contraceptives, male contraception remains relatively limited. Currently, men have access to barrier contraception with condoms, vasectomy and withdrawal methods. Although there are numerous male hormonal contraceptives in development, condoms remain the most accessible and widely used means of birth control and protection against sexually transmitted diseases.

Objective
To provide a comprehensive overview of the history of male barrier contraception.

Methods
An extensive literature review was performed to unearth the rich history of male condoms.

Results
The origins of the condom trace back to 3000 BC when King Minos of Crete employed a goat’s bladder as a protective sheath against his semen, which was believed to contain “scorpions and serpents.” In 1000 BC, ancient Egyptians used linen sheaths secured with ribbons to safeguard their penises from diseases. Interestingly, the early use of condoms was for disease prevention, with contraceptive potential not yet realized. Even the Romans, despite their sophistication, did not recognize condoms as contraceptives but rather tools for public health. The modern history of condoms witnessed a shift towards their contraceptive utility. During the English Civil War, soldiers were provided with animal intestine sheaths to prevent the spread of syphilis, a common cause of mortality. Around the same time, King Charles II, who was troubled with illegitimate offspring, was advised by his doctor, aptly named Colonel Condom, to use animal sheaths for protection. By the 1700s, condom use for contraception was well documented, and England’s fertility rate had significantly reduced due to its widespread adoption. The 1800s brought new developments, including chemical treatments to enhance the comfort of the condom with “skin-like feel.” In the late 1800s, American inventor Charles Goodyear introduced the first rubber condom, revolutionizing the industry with a more malleable, durable, and cost-effective to those made from animal intestines or bladders. The 1900s saw the mass production of condoms and easier access for the general population. Ongoing innovations, such as latex, further improved their durability, flexibility, stretchability, comfort, and pleasure.

Conclusions
The historical journey of condoms sheds light on the evolution of men's health and reproductive practices. Initially driven by concerns in public health and disease prevention, condoms have played a vital role in influencing societal issues such as gender equitable birth control, religious perspectives on contraceptives, and societal attitudes towards sexuality. Understanding this history is instrumental in shaping the future of male contraception.

Disclosure
Any of the authors act as a consultant, employee or shareholder of an industry for: Boston Scientific, Halozyme Therapeutics and Endo Pharmaceuticals.